THIS CIRCULAR IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION

If you are in any doubt as to any aspect of this circular or as to the action to be taken, you should consult a stockbroker or other registered dealer in securities, a bank manager, solicitor, professional accountant or other professional adviser.

If you have sold or transferred all your shares in **Biosino Bio-Technology and Science Incorporation**, you should at once hand this circular, together with the enclosed form of proxy, to the purchaser or transferee or to the bank, stockbroker or other agent through whom the sale was effected for transmission to the purchaser or transferee.

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this circular, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this circular.

中生北控生物科技股份有限公司
BIOSINO BIO-TECHNOLOGY AND SCIENCE INCORPORATION

(a joint stock limited company incorporated in the People's Republic of China with limited liability)

(Stock Code: 8247)

(1) PROPOSED APPOINTMENTS AND RE-APPOINTMENTS OF DIRECTORS; (2) PROPOSED AMENDMENT TO THE ARTICLES OF ASSOCIATION; (3) PROPOSED AMENDMENT TO THE RULES OF PROCEDURE OF THE BOARD OF DIRECTORS; AND (4) NOTICE OF THE EXTRAORDINARY GENERAL MEETING

A notice convening the extraordinary general meeting (the "**Extraordinary General Meeting**") of Biosino Bio-Technology and Science Incorporation (the "**Company**") to be held at No. 27 Chaoqian Road, Science and Technology Industrial Park, Changping District, Beijing, the People's Republic of China on Monday, 9 February 2026 at 10:00 a.m. is set out on pages 16 to 18 of this circular.

A form of proxy for use at the Extraordinary General Meeting is enclosed with the notice of the Extraordinary General Meeting and such form of proxy is also published on the websites of Hong Kong Exchanges and Clearing Limited (www.hkexnews.hk) and the Company (www.zhongsheng.com.cn). Whether or not you intend to attend the Extraordinary General Meeting, you are requested to complete and return the form of proxy in accordance with the instructions printed thereon not less than 24 hours before the time fixed for holding the Extraordinary General Meeting or any adjournment thereof (as the case may be). Completion and return of the form of proxy will not preclude you from attending the Extraordinary General Meeting and voting in person if you so wish and in such event, the form of proxy shall be deemed to be revoked. For the avoidance of doubt, holders of any Treasury Shares shall abstain from voting at general meetings in respect of any Treasury Shares held by them, if any.

This circular will remain on the website of Hong Kong Exchanges and Clearing Limited on the "Latest Listed Company Information" page for at least 7 days from the date of its posting.

23 January 2026

CHARACTERISTICS OF GEM

GEM has been positioned as a market designed to accommodate small and mid-sized companies to which a higher investment risk may be attached than other companies listed on the Stock Exchange. Prospective investors should be aware of the potential risks of investing in such companies and should make the decision to invest only after due and careful consideration.

Given that the companies listed on GEM are generally small and mid-sized companies, there is a risk that securities traded on GEM may be more susceptible to high market volatility than securities traded on the Main Board of the Stock Exchange and no assurance is given that there will be a liquid market in the securities traded on GEM.

CONTENTS

Page

Characteristics of GEM i

Definitions 1

Letter from the Board

1. Introduction 4
2. Proposed Appointments and Re-Appointments of Directors 4
3. Proposed Amendment to the Articles of Association 6
4. Proposed Amendment to the Rules of Procedure of the Board of Directors 7
5. Extraordinary General Meeting and Proxy Arrangement 7
6. Recommendation 8
7. Additional Information 8

Appendix – The Biographies of Directors Proposed to be Appointed and Re-appointed 9

Notice of the Extraordinary General Meeting 16

In this circular, unless the context otherwise requires, the following expressions have the following meanings:

"Articles of Association" or "Articles"	the articles of association of the Company, as amended from time to time
"Audit Committee"	the audit committee of the Board
"Board"	the board of Directors
"Company"	Biosino Bio-Technology and Science Incorporation (中生北控生物科技股份有限公司), a joint stock limited company established in the PRC with limited liability on 26 April 2001
"Company Law"	the Company Law of the PRC (《中華人民共和國公司法》), as amended from time to time
"Director(s)"	the director(s) of the Company
"Domestic Share(s)"	ordinary share(s) of nominal value of RMB1.00 each in the share capital of the Company which are subscribed for or credited as paid up in Renminbi
"Extraordinary General Meeting"	the extraordinary general meeting of the Company to be held at No. 27 Chaoqian Road, Science and Technology Industrial Park, Changping District, Beijing, the PRC on Monday, 9 February 2026 at 10:00 a.m., to consider and, if appropriate, to approve the resolutions contained in the notice of the Extraordinary General Meeting which is set out on pages 16 to 18 of this circular, or any adjournment thereof
"GEM"	GEM of the Stock Exchange
"GEM Listing Rules"	the Rules Governing the Listing of Securities on GEM
"Group"	the Company and its subsidiaries
"H Share(s)"	overseas listed foreign shares in the ordinary share capital of the Company, with nominal value of RMB1.00 each, which are listed on GEM
"Hong Kong"	the Hong Kong Special Administrative Region of the PRC

"Latest Practicable Date"	21 January 2026, being the latest practicable date prior to the publication of this circular for ascertaining certain information in this circular
"Nomination Committee"	the nomination committee of the Board
"PRC"	the People's Republic of China, which for the purpose of this circular excludes Hong Kong, Macau and Taiwan
"Remuneration Committee"	the remuneration committee of the Board
"RMB"	Renminbi, the lawful currency of the PRC
"SFO"	the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong), as amended from time to time
"Share(s)"	Domestic Shares and H Shares
"Shareholders"	the shareholders of the Company
"Stock Exchange"	The Stock Exchange of Hong Kong Limited
"Treasury Shares"	has the meaning ascribed to it under the GEM Listing Rules
"%"	per cent

In this circular, the English names of the PRC entities or enterprises are translations of their Chinese names. In the event of any inconsistency, the Chinese names shall prevail.

中生北控生物科技股份有限公司
BIOSINO BIO-TECHNOLOGY AND SCIENCE INCORPORATION

(a joint stock limited company incorporated in the People's Republic of China with limited liability)

(Stock Code: 8247)

Chairman and executive Director
Mr. Chen Zhengyong (陳正永先生)

Vice-chairman and executive Director
Mr. Li Zhonghua (李忠華先生)

President and executive Director
Mr. Chen Peng (陳鵬先生)

Vice chairman and non-executive Director
Mr. Yang Peng (楊鵬先生)

Non-executive Directors
Dr. Gao Guangxia (高光俠博士)
Dr. Shen Sheng (沈勝博士)

Independent non-executive Directors
Prof. Shen Zuojun (沈佐君教授)
Prof. Shen Jiangang (沈劍剛教授)
Dr. He Xin (何欣博士)
Mr. Fan Xiaoliang (范曉亮先生)

Registered office and principal place of business in the PRC:
No. 27 Chaoqian Road
Science and Technology Industrial Park
Changping District
Beijing, PRC

Principal place of business in Hong Kong:
66/F., Central Plaza
18 Harbour Road, Wanchai
Hong Kong

23 January 2026

To the Shareholders

Dear Sir/Madam,

(1) PROPOSED APPOINTMENTS AND RE-APPOINTMENTS OF DIRECTORS; (2) PROPOSED AMENDMENT TO THE ARTICLES OF ASSOCIATION; (3) PROPOSED AMENDMENT TO THE RULES OF PROCEDURE OF THE BOARD OF DIRECTORS; AND (4) NOTICE OF THE EXTRAORDINARY GENERAL MEETING

1. INTRODUCTION

The purpose of this circular is to give you, (i) information regarding certain resolutions to be proposed at the Extraordinary General Meeting to enable you to make an informed decision on whether to vote for or against those resolutions at the Extraordinary General Meeting; and (ii) the notice of the Extraordinary General Meeting.

2. PROPOSED APPOINTMENTS AND RE-APPOINTMENTS OF DIRECTORS

The term of office of the current eighth session of the members of the Board will expire this year. At the Board meeting held on 19 January 2026, the Board proposed to conduct the re-election for the ninth session of the Board (the "**Proposed Board Re-election**") subject to the approval of the Shareholders at the Extraordinary General Meeting.

Save and except for Mr. Yang Peng, Dr. Gao Guangxia, Dr. Shen Sheng, Prof. Shen Zuojun and Dr. He Xin, who will not offer themselves for re-appointment as they would like to devote more time on their other commitments, the remaining Directors namely, Mr. Chen Zhengyong, Mr. Li Zhonghua, Mr. Chen Peng, Prof. Shen Jiangang and Mr. Fan Xiaoliang, will offer themselves for re-appointment at the Extraordinary General Meeting.

Ordinary resolutions will be proposed at the Extraordinary General Meeting to re-appoint each of Mr. Chen Zhengyong, Mr. Li Zhonghua and Mr. Chen Peng as an executive Director, and to re-appoint each of Prof. Shen Jiangang and Mr. Fan Xiaoliang as an independent non-executive Director of the ninth session of the Board.

It is proposed that Ms. Kang Rui will be appointed as a non-executive Director, and Prof. Jin Tengchuan will be appointed as an independent non-executive Director of the ninth session of the Board and ordinary resolutions will be proposed at the Extraordinary General Meeting to such effect. Biographical details of each of the proposed Directors to be appointed and re-appointed are set out in the Appendix to this circular.

Upon the Proposed Board Re-election becoming effective at the conclusion of the Extraordinary General Meeting, the members of the Audit Committee, the Nomination Committee and the Remuneration Committee of the ninth session of the Board will be as follows:

(i) The Audit Committee

Chairman: Mr. Fan Xiaoliang

Members: Prof. Shen Jiangang and Prof. Jin Tengchuan

(ii) The Nomination Committee

Chairman: Prof. Jin Tengchuan

Members: Mr. Fan Xiaoliang and Prof. Shen Jiangang

(iii) The Remuneration Committee

Chairman: Prof. Shen Jiangang

Members: Mr. Fan Xiaoliang and Prof. Jin Tengchuan

The nominees for the ninth session of the Board include three independent non-executive Directors, representing more than one-third of the Board and thereby satisfying the relevant requirements under the GEM Listing Rules. Apart from the two nominees proposed for re-appointment as independent non-executive Directors, the Company also identified a suitable new independent non-executive Director candidate through multiple channels. The criteria for such candidate include but are not limited to the candidate's character and integrity, professional qualifications, skills, knowledge and experience, independence, contribution to Board diversity, willingness to devote adequate time to discharge duties as a Board member and such other criteria that are appropriate to the business of the Company. In considering the proposed re-appointments and appointment of independent non-executive Directors, the Nomination Committee and the Board have taken into account the following factors:

1. The nominees for independent non-executive Directors have extensive and solid experience in different sectors including finance, accounting, management, research experience in Chinese medicine and biological sciences, clinical laboratory, etc. Their education, background, experience and practical experience enable them to provide valuable and diversified opinions. During their respective tenure, Prof. Shen Jiangang and Mr. Fan Xiaoliang have proactively and diligently carried out their duties as independent non-executive Directors and have provided valuable independent advice on the affairs of the Company from time to time with their professional knowledge and comprehensive experience.

2. The Company has conducted an assessment on their independence and is of the view that each of them complies with the independence requirement pursuant to Rule 5.09 of the GEM Listing Rules and that they are considered as independent.

3. None of the nominees for independent non-executive Directors holds position as a director in seven or more listed companies. They are able to devote sufficient time and attention to the Company.

Accordingly, the Nomination Committee and the Board are of the view that the re-appointments and appointment of the three nominees to be independent non-executive Directors can enhance the level of management of the Company by virtue of their professional knowledge and extensive experience, while promoting the independence and objectiveness in decision-making of the Board and the comprehensive and impartial supervision of the management of the Company, which is in the interests of the Company and the Shareholders as a whole.

3. PROPOSED AMENDMENT TO THE ARTICLES OF ASSOCIATION

In light of the restructuring of the Board composition, the Board resolved to amend article 91 of the Articles of Association as below:

Before amendment	**After amendment**
91. The Company shall have a Board of Directors. The Board of Directors shall consist of at least nine directors and there shall be one (1) Chairman and two (2) Vice-chairmen.	91. The Company shall have a Board of Directors. The Board of Directors shall consist of at least ~~nine~~**seven** directors and there shall be one (1) Chairman and ~~two (2) Vice-chairmen~~**one (1) Vice-chairman**.
The Board of Directors shall have executive directors, non-executive directors and independent non-executive directors.	The Board of Directors shall have executive directors, non-executive directors and independent non-executive directors.
The external directors (meaning those who do not hold any positions within the Company and carrying the same meaning below) shall make up more than half of members of the Board of Directors, of which one-third shall be independent (non-executive) directors (meaning directors who are independent from the Company's shareholders and do not hold any positions within the Company).	The external directors (meaning those who do not hold any positions within the Company and carrying the same meaning below) shall make up more than half of members of the Board of Directors, of which one-third shall be independent (non-executive) directors (meaning directors who are independent from the Company's shareholders and do not hold any positions within the Company).

The Articles of Association are prepared in Chinese, and the English version is for reference only. In case of any discrepancy between the Chinese and English versions, the Chinese version shall prevail.

According to the Articles of Association and the relevant laws and regulations, the proposed amendment to the Articles of Association will take effect subject to the approval of the Shareholders at the Extraordinary General Meeting by way of special resolution. A special resolution in relation to the proposed amendment to the Articles of Association will be proposed at the Extraordinary General Meeting for the approval by the Shareholders.

The legal advisers to the Company as to the PRC law and Hong Kong law have confirmed that the proposed amendment to the Articles of Association conform with the requirements under the PRC laws and the GEM Listing Rules, respectively. The Company, on the other hand, has confirmed that there is nothing unusual about the proposed amendment to the Articles of Association for a PRC company whose H shares are listed on the Stock Exchange.

4. PROPOSED AMENDMENT TO THE RULES OF PROCEDURE OF THE BOARD OF DIRECTORS

In light of the restructuring of the Board composition, the Board resolved to amend article 3 of the Rules of Procedure of the Board of Directors as below:

Before amendment	**After amendment**
3. The Board consists of 9 directors, including independent directors accounting for no less than 1/3 of the quorum. The Board of Directors shall have a chairman and 2 vice chairmen.	3. The Board consists of ~~9~~7 directors, including independent directors accounting for no less than 1/3 of the quorum. The Board of Directors shall have a chairman and ~~2 vice chairmen~~**a vice chairman**.

The Rules of Procedure of the Board of Directors are prepared in Chinese, and the English version is for reference only. In case of any discrepancy between the Chinese and English versions, the Chinese version shall prevail.

A special resolution in relation to the proposed amendment to the Rules of Procedure of the Board of Directors will be proposed at the Extraordinary General Meeting for the approval by the Shareholders.

5. EXTRAORDINARY GENERAL MEETING AND PROXY ARRANGEMENT

The notice of the Extraordinary General Meeting is set out on pages 16 to 18 of this circular. At the Extraordinary General Meeting, resolutions will be proposed to approve, *inter alia*, (i) the proposed appointments and re-appointments of Directors; and (ii) the proposed amendments to the Articles of Association and the Rules of Procedure of the Board of Directors.

Pursuant to Rule 17.47(4) of the GEM Listing Rules, any vote of Shareholders at a general meeting must be taken by poll. Accordingly, all resolutions will be put to vote by way of poll at the Extraordinary General Meeting. An announcement on the poll results will be made by the Company after the Extraordinary General Meeting in the manner prescribed under Rules 17.47(5) of the GEM Listing Rules.

To the best knowledge, information and belief of the Directors having made all reasonable enquiries, as at the Latest Practicable Date, no Shareholder had a material interest in any resolution to be proposed at the Extraordinary General Meeting and accordingly, no Shareholder is required to abstain from voting at the Extraordinary General Meeting.

A form of proxy for use at the Extraordinary General Meeting is enclosed with the notice of the Extraordinary General Meeting and such form of proxy is also published on the websites of Hong Kong Exchanges and Clearing Limited (www.hkexnews.hk) and the Company (www.zhongsheng.com.cn). Whether or not you intend to attend the Extraordinary General Meeting, you are requested to complete and return the form of proxy in accordance with the instructions printed thereon not less than 24 hours before the time fixed for holding the Extraordinary General Meeting or any adjournment thereof (as the case may be). Completion and return of the form of proxy will not preclude you from attending the Extraordinary General Meeting and voting in person if you so wish and in such event, the form of proxy shall be deemed to be revoked. For the avoidance of doubt, holders of any Treasury Shares shall abstain from voting at general meetings in respect of any Treasury Shares held by them, if any.

6. RECOMMENDATION

The Directors believe that all resolutions proposed for consideration and approval by the Shareholders at the Extraordinary General Meeting are in the best interests of the Company and the Shareholders as a whole. Accordingly, the Directors recommend that all the Shareholders should vote in favour of all the resolutions to be proposed at the Extraordinary General Meeting as set out in the notice of the Extraordinary General Meeting.

7. ADDITIONAL INFORMATION

Your attention is drawn to the additional information as set out in the Appendix to this circular.

Yours faithfully,
For and on behalf of the Board
Biosino Bio-Technology and Science Incorporation
Chen Zhengyong
Chairman

The following are the particulars of the Directors proposed to be appointed and re-appointed at the Extraordinary General Meeting:

EXECUTIVE DIRECTORS

Mr. CHEN Zhengyong（陳正永先生）

Mr. CHEN Zhengyong（陳正永先生）, aged 62, is an executive Director and the chairman of the Board. Mr. Chen Zhengyong joined the Company in May 2023. He has over 40 years of experience in the PRC medical testing and in vitro diagnostic industry. From 1983 to 1993, he was employed at Chengdu Tenth Hospital*（成都市第十醫院）where he was responsible for diagnostic testing. Since 1994, he has been engaged in the business of precision medicine and in vitro diagnostic. He has served as the chairman of the board of a number of companies including Sichuan Zhong Sheng Medical Devices Co., Ltd.*（四川中生醫療器械有限責任公司）since 2012, Sichuan Century Tongchang Health Management Co., Ltd.*（四川世紀同昌健康管理有限責任公司）since 2015 and Chengdu Tongchang Medical Laboratory Co., Ltd.*（成都同昌醫學檢驗所有限公司）since 2017.

Mr. Chen Zhengyong obtained his diploma from Chongqing Medical and Pharmaceutical College（重慶醫藥高等專科學校）in clinical laboratory（檢驗專業）in 1983. He studied Chinese language and literature（漢語言文學專業）at Sichuan Broadcast Television University*（四川省廣播電視大學）(currently known as Sichuan Open University（四川開放大學）) from 1985 to 1988, studied Master of Business Administration at Sichuan University of Finance and Economics（四川財經大學）from 2014 to 2016 and studied Master of Business Administration at Peking University（北京大學）from 2018 to 2020.

The Company proposes to re-appoint Mr. Chen Zhengyong as an executive Director to hold office for a term of three years until the expiration of the term of the ninth session of the Board. Subject to the Shareholders' approval at the Extraordinary General Meeting, his emoluments will be determined by the Board and the Remuneration Committee with reference to his duties and responsibilities, the performance of the Group and the prevailing market conditions.

As at the Latest Practicable Date, Sichuan Zhongsheng Medical Instrument Co., Ltd. ("**Sichuan Zhongsheng**") owned 10,000,000 Domestic Shares. As the equity interests of Sichuan Zhongsheng were owned as to 77.94% by Mr. Chen Zhengyong, he is deemed to be interested in the Domestic Shares owned by Sichuan Zhongsheng pursuant to the SFO. Accordingly, he is deemed to be interested in the 10,000,000 Domestic Shares owned by Sichuan Zhongsheng.

Save as disclosed above, as at the Latest Practicable Date, Mr. Chen Zhengyong did not (i) hold any other positions in the Company or any of its subsidiaries; (ii) hold any directorship in any public companies the securities of which are listed on any securities markets in Hong Kong or overseas in the past three years nor did he have other major appointments and professional qualifications; (iii) have any relationships with any Directors, senior management, substantial shareholders or controlling shareholders of the Company; and (iv) have any interest in Shares within the meaning of Part XV of the SFO.

Save as disclosed above, there are no other matters that are required to be disclosed pursuant to Rule 17.50(2)(h) to (v) of the GEM Listing Rules and there are no other matters relating to the re-appointment of Mr. Chen Zhengyong that need to be brought to the attention of the Shareholders.

Mr. LI Zhonghua（李忠華先生）

Mr. LI Zhonghua（李忠華先生）("Mr. Li"), aged 62, is an executive Director and the vice chairman of the Board. Mr. Li joined the Company in May 2023. Mr. Li has experience working as a supervisor teach in medical diagnostic profession, a secretary and deputy secretary of the Youth League Committee（團委書記及副書記）, a clinical laboratory doctor at the hospital. Currently, Mr. Li serves as the deputy director of the Pharmaceutical Professional Committee* of the Yunnan Provincial Party Committee of the Peasants and Workers Democratic Party*（農工民主黨雲南省委藥物專業委員會副主任）. From 1993 to December 1997, Mr. Li worked at Shanghai Kehua Biotechnology Co., Ltd.*（上海科華生物科技有限公司）. In 1998, Mr. Li commenced his own business and was a senior management personnel that inspects medical equipment products in Yunnan Province. Mr. Li founded Kunming Huasheng Technology Co., Ltd.*（昆明華聖科技有限公司）and Yunnan Guoke Kangyi Biotechnology Co., Ltd.*（雲南國科康儀生物科技有限公司）. Mr. Li was a graduate student at Kunming Medical University（昆明醫科大學）(previously known as Kunming Medical College（昆明醫學院）) and obtained his EMBA degree from Peking University HSBC Business School.

The Company proposes to re-appoint Mr. Li as an executive Director to hold office for a term of three years until the expiration of the term of the ninth session of the Board. Subject to the Shareholders' approval at the Extraordinary General Meeting, his emoluments will be determined by the Board and the Remuneration Committee with reference to his duties and responsibilities, the performance of the Group and the prevailing market conditions.

As at the Latest Practicable Date, other than being the father of Mr. Li Yangyixiong（李楊一雄）, a substantial Shareholder, Mr. Li did not have any relationship with the Directors, senior management, substantial or controlling shareholders of the Company as defined in the GEM Listing Rules.

Save as disclosed above, as at the Latest Practicable Date, Mr. Li did not (i) hold any other positions in the Company or any of its subsidiaries; (ii) hold any directorship in any public companies the securities of which are listed on any securities markets in Hong Kong or overseas in the past three years nor did he have other major appointments and professional qualifications; (iii) have any relationships with any Directors, senior management, substantial shareholders or controlling shareholders of the Company; and (iv) have any interest in Shares within the meaning of Part XV of the SFO.

Save as disclosed above, there are no other matters that are required to be disclosed pursuant to Rule 17.50(2)(h) to (v) of the GEM Listing Rules and there are no other matters relating to the re-appointment of Mr. Li that need to be brought to the attention of the Shareholders.

Mr. CHEN Peng（陳鵬先生）

Mr. CHEN Peng（陳鵬先生）, aged 52, is an executive Director and the president of the Company. Mr. Chen Peng joined the Company in December 2021. He graduated from Anhui University of Chinese Medicine（安徽中醫學院）with a bachelor's degree in Integrated Chinese and Western Medicine（中西醫結合臨床專業）in 1998. He served as the technical director of Shanghai Fosun High-tech (Group) Co., Ltd.*（上海複星高科技（集團）公司）, a director of Anhui Guoke Kangyi Medical Technology Co., Ltd.*（安徽國科康儀醫療科技有限公司）and Hefei Guoke Kangyi Medical Laboratory Co., Ltd.*（合肥國科康儀醫學檢驗實驗室有限公司）, the chairman and president of Hefei Anhui Meikang Hospital Investment Management Co., Ltd.（合肥安徽美康醫院投資管理股份有限公司）, the general manager of Guoke Health Hospital Industry (Hefei) Co., Ltd.*（國科健康醫院產業（合肥）有限公司）, the chairman of Guoke Health Information Technology (Anhui) Co., Ltd.（國科健康信息科技（安徽）有限公司）and the chairman of Step Stone (Suzhou) Biotechnology Co., Ltd.（踏石（蘇州）生物技術有限公司）.

The Company proposes to re-appoint Mr. Chen Peng as an executive Director to hold office for a term of three years until the expiration of the term of the ninth session of the Board. Subject to the Shareholders' approval at the Extraordinary General Meeting, his emoluments will be determined by the Board and the Remuneration Committee with reference to his duties and responsibilities, the performance of the Group and the prevailing market conditions.

As at the Latest Practicable Date, Jingning Guoke Kangyi Enterprise Management Center LLP*（景寧國科康儀企業管理中心（有限合夥））（"**Jingning**"）owned 11,330,334 Domestic Shares and Mr. Chen Peng owns 99.5% of equity interests in Jingning. Accordingly, he is deemed to be interested in the 11,330,334 Domestic Shares owned by Jingning.

Save as disclosed above, as at the Latest Practicable Date, Mr. Chen Peng did not (i) hold any other positions in the Company or any of its subsidiaries; (ii) hold any directorship in any public companies the securities of which are listed on any securities markets in Hong Kong or overseas in the past three years nor did he have other major appointments and professional qualifications; (iii) have any relationships with any Directors, senior management, substantial shareholders or controlling shareholders of the Company; and (iv) have any interest in Shares within the meaning of Part XV of the SFO.

Save as disclosed above, there are no other matters that are required to be disclosed pursuant to Rule 17.50(2)(h) to (v) of the GEM Listing Rules and there are no other matters relating to the re-appointment of Mr. Chen Peng that need to be brought to the attention of the Shareholders.

NON-EXECUTIVE DIRECTOR

Ms. KANG Rui（康睿女士）

Ms. KANG Rui（康睿女士）("Ms. Kang"), aged 25, is a proposed non-executive Director. Ms. Kang obtained a bachelor's degree in Broadcasting and Hosting Arts from Shandong Youth University of Political Science in June 2022. Since February 2023, Ms. Kang has been employed by Boke Holdings Group Co., Ltd.*（博科控股集團有限公司）, where she currently serves as an administrative manager and is primarily responsible for the establishment of institutional systems, planning of large-scale events, and internal administrative management. Ms. Kang is also a director of Shandong Biobase Zhongsheng Technology Co., Ltd.*（山東博科中生科技有限公司）, a substantial shareholder of the Company.

Subject to the Shareholders' approval of Ms. Kang's appointment as a non-executive Director, the Company will enter into a service agreement with Ms. Kang and her term of service with the Company will end at the expiration of the term of the ninth session of the Board. Her remuneration will be determined by the Board and the Remuneration Committee with reference to her duties and responsibilities, the performance of the Group and the prevailing market conditions.

Save as disclosed above, as at the Latest Practicable Date, Ms. Kang did not (i) hold any other positions in the Company or any of its subsidiaries; (ii) hold any directorship in any public companies the securities of which are listed on any securities markets in Hong Kong or overseas in the past three years nor did he have other major appointments and professional qualifications; (iii) have any relationships with any Directors, senior management, substantial shareholders or controlling shareholders of the Company; and (iv) have any interest in Shares within the meaning of Part XV of the SFO.

Save as disclosed above, there are no other matters that are required to be disclosed pursuant to Rule 17.50(2)(h) to (v) of the GEM Listing Rules and there are no other matters relating to the appointment of Ms. Kang that need to be brought to the attention of the Shareholders.

INDEPENDENT NON-EXECUTIVE DIRECTORS

Prof. Jin Tengchuan（金騰川教授）

Prof. Jin Tengchuan（金騰川教授）("Prof. Jin"), aged 45, is a proposed independent non-executive Director. Prof. Jin obtained dual bachelor's degrees in biophysics and business administration from University of Science and Technology of China in 2003. He also obtained a doctoral degree in biochemistry and molecular biology from Illinois Institute of Technology in the United States in 2008. From 2008 to 2014, he served successively as Postdoctoral Fellow and Research Fellow at the National Institutes of Health (NIH), National Institute of Allergy and Infectious Diseases (NIAID) in the United States. In 2015, he was appointed as Specially Appointed Researcher and PhD Supervisor at the School of Life Sciences, University of Science and Technology of China, and was promoted to Professor in 2021. He has published in journals including Immunity, Cell Research, Journal of Experimental Medicine, Nature Communications, Signal Transduction and Targeted Therapy, Nucleic Acids Research, Cell Discovery, Protein & Cell, Cellular & Molecular Immunology, and Cell Reports. Since 2025, he has served as Executive Editor-in-Chief of iNew Medicine and as an editorial board member of Allergy Medicine and Bulletin of Obstetrics & Gynecology.

Subject to the Shareholders' approval of Prof. Jin's appointment as an independent non-executive Director, the Company will enter into a service agreement with Prof. Jin and his term of service with the Company will end at the expiration of the term of the ninth session of the Board. His remuneration will be determined by the Board and the Remuneration Committee with reference to his duties and responsibilities, the performance of the Group and the prevailing market conditions.

Save as disclosed above, as at the Latest Practicable Date, Prof. Jin did not (i) hold any other positions in the Company or any of its subsidiaries; (ii) hold any directorship in any public companies the securities of which are listed on any securities markets in Hong Kong or overseas in the past three years nor did he have other major appointments and professional qualifications; (iii) have any relationships with any Directors, senior management, substantial shareholders or controlling shareholders of the Company; and (iv) have any interest in Shares within the meaning of Part XV of the SFO.

Prof. Jin has met the independence criteria set out in Rule 5.09 of the GEM Listing Rules. Save as disclosed above, there are no other matters that are required to be disclosed pursuant to Rule 17.50(2)(h) to (v) of the GEM Listing Rules and there are no other matters relating to the appointment of Prof. Jin that need to be brought to the attention of the Shareholders.

Prof. Shen Jiangang（沈劍剛教授）

Prof. Shen Jiangang（沈劍剛教授）("Prof. Shen"), aged 62, is an independent non-executive Director. Prof. Shen joined the Company in February 2023. Prof. Shen acted as a professor and chairman of the Departmental Research Postgraduate Committee at School of Chinese Medicine of The University of Hong Kong since February 2022. From July 2014 to February 2020, Prof. Shen acted as a professor and associate director (research) of School of Chinese Medicine at The University of Hong Kong. From January 2013 to July 2014, Prof. Shen acted as a professor and assistant director (research) of School of Chinese Medicine at The University of Hong Kong. From November 2005 to January 2007, Prof. Shen acted as an assistant professor at School of Chinese Medicine of The Chinese University of Hong Kong. From August 2004 to December 2005, Prof. Shen served as an assistant professor (research) at College of Pharmacy, Health Science Center, University of New Mexico in the United States. From September 2001 to September 2004, Prof. Shen served as a research assistant professor at the Department of Medicine of The University of Hong Kong. From August 1999 to September 2001, Prof. Shen was employed as a research scientist at National EPR Center, Department of Radiology at Dartmouth Medical School in the United States. From July 1995 to July 1998, Prof. Shen acted as an associate professor and associate director at Institute of Chinese Medicine, NanFang Hospital, First Military Medical University (currently known as Southern Medical University) in China. From July 1990 to July 1995, Prof. Shen was a lecturer at Institute of Chinese Medicine, Nan-Fang Hospital, First Military Medical University in China.

The Company proposes to re-appoint Prof. Shen as an independent non-executive Director to hold office for a term of three years until the expiration of the term of the ninth session of the Board. Subject to the Shareholders' approval at the Extraordinary General Meeting, his emoluments will be determined by the Board and the Remuneration Committee with reference to his duties and responsibilities, the performance of the Group and the prevailing market conditions.

Save as disclosed above, as at the Latest Practicable Date, Prof. Shen did not (i) hold any other positions in the Company or any of its subsidiaries; (ii) hold any directorship in any public companies the securities of which are listed on any securities markets in Hong Kong or overseas in the past three years nor did he have other major appointments and professional qualifications; (iii) have any relationships with any Directors, senior management, substantial shareholders or controlling shareholders of the Company; and (iv) have any interest in Shares within the meaning of Part XV of the SFO.

Prof. Shen has met the independence criteria set out in Rule 5.09 of the GEM Listing Rules. Save as disclosed above, there are no other matters that are required to be disclosed pursuant to Rule 17.50(2)(h) to (v) of the GEM Listing Rules and there are no other matters relating to the re-appointment of Prof. Shen that need to be brought to the attention of the Shareholders.

Mr. Fan Xiaoliang（范曉亮先生）

Mr. Fan Xiaoliang（范曉亮先生）("Mr. Fan"), aged 60, is an independent non-executive Director. Mr. Fan joined the Company in July 2025. Mr. Fan is a certified public accountant, tax advisor, and asset appraiser in the PRC. He is currently a partner at Zhongxingcai Guanghua Certified Public Accountants LLP*（中興財光華會計師事務所(特殊普通合夥)), an executive director at Beijing Shiji Shuitong Tax Firm*（北京世紀税通税務師事務所）and an independent director of Zhuhai Hokai Medical Instruments Co. Ltd.（珠海市和佳醫療設備有限公司）(previously listed on the Shenzhen Stock Exchange and delisted in July 2023). He obtained a bachelor's degree in management from Anhui Institute of Finance and Trade (currently known as Anhui University of Finance and Economics) in December 2000. Mr. Fan has been involved in projects such as annual audits of listed companies, audits for mergers and acquisitions, business management consulting and tax planning.

The Company proposes to re-appoint Mr. Fan as an independent non-executive Director to hold office for a term of three years until the expiration of the term of the ninth session of the Board. Subject to the Shareholders' approval at the Extraordinary General Meeting, his emoluments will be determined by the Board and the Remuneration Committee with reference to his duties and responsibilities, the performance of the Group and the prevailing market conditions.

Save as disclosed above, as at the Latest Practicable Date, Mr. Fan did not (i) hold any other positions in the Company or any of its subsidiaries; (ii) hold any directorship in any public companies the securities of which are listed on any securities markets in Hong Kong or overseas in the past three years nor did he have other major appointments and professional qualifications; (iii) have any relationships with any Directors, senior management, substantial shareholders or controlling shareholders of the Company; and (iv) have any interest in Shares within the meaning of Part XV of the SFO.

Mr. Fan has met the independence criteria set out in Rule 5.09 of the GEM Listing Rules. Save as disclosed above, there are no other matters that are required to be disclosed pursuant to Rule 17.50(2)(h) to (v) of the GEM Listing Rules and there are no other matters relating to the re-appointment of Mr. Fan that need to be brought to the attention of the Shareholders.

中生北控生物科技股份有限公司
BIOSINO BIO-TECHNOLOGY AND SCIENCE INCORPORATION

(a joint stock limited company incorporated in the People's Republic of China with limited liability)

(Stock Code: 8247)

NOTICE OF THE EXTRAORDINARY GENERAL MEETING

NOTICE IS HEREBY GIVEN that an extraordinary general meeting (the "**Meeting**") of Biosino Bio-Technology and Science Incorporation (the "**Company**") will be held at No. 27 Chaoqian Road, Science and Technology Industrial Park, Changping District, Beijing, the People's Republic of China (the "**PRC**") on Monday, 9 February 2026 at 10:00 a.m. for the following purposes:-

AS ORDINARY RESOLUTIONS

1. To consider and approve the appointments and re-appointments of the following persons as directors of the Company (the "**Director(s)**"), and authorise the board (the "**Board**") of Directors to fix their remuneration and to enter into service contracts with them subject to such terms and conditions as the Board shall think fit and to do all such acts and things to give effect to such matters:-

   (a) the re-appointment of Mr. Chen Zhengyong as an executive Director;

   (b) the re-appointment of Mr. Li Zhonghua as an executive Director;

   (c) the re-appointment of Mr. Chen Peng as an executive Director;

   (d) the re-appointment of Prof. Shen Jiangang as an independent non-executive Director;

   (e) the re-appointment of Mr. Fan Xiaoliang as an independent non-executive Director;

   (f) the appointment of Ms. Kang Rui as a non-executive Director; and

   (g) the appointment of Prof. Jin Tengchuan as an independent non-executive Director.

AS SPECIAL RESOLUTIONS

2. To consider and approve the proposed amendment to the articles of association of the Company.

3. To consider and approve the proposed amendment to the Rules of Procedure of the Board of Directors.

For and on behalf of the Board
Biosino Bio-Technology and Science Incorporation
Tung Woon Cheung, Eric
Company Secretary

Beijing, the PRC, 23 January 2026

Notes:

1. The record date for determining the eligibility of shareholders of the Company (the "**Shareholder(s)**") to attend and vote at the Extraordinary General Meeting is Friday, 6 February 2026. To qualify for attendance and voting at the Extraordinary General Meeting (or any adjournment thereof), documents on transfers of H Shares must be lodged with the Company's H share registrar in Hong Kong, Tricor Investor Services Limited, at 17/F, Far East Finance Centre, 16 Harcourt Road, Hong Kong, not later than 4:30 p.m. on Friday, 6 February 2026. Holders of Domestic Shares should contact the secretary to the Board (the "**Secretary to the Board**") (whose contact details are: (i) address: No. 27 Chaoqian Road, Science and Technology Industrial Park, Changping District, Beijing, the PRC; and (ii) fax: (86) 10 8011 7026) for details concerning registration of transfers of Domestic Shares.

2. Each holder of H Shares who is entitled to attend and vote at the Extraordinary General Meeting (or any adjournment thereof) may, by completing the form of proxy of the Company, appoint one or more proxies to attend and vote at the Extraordinary General Meeting (or any adjournment thereof) on his behalf. A proxy needs not be a Shareholder.

3. Holders of H Shares must use the form of proxy of the Company for appointing a proxy and the appointment must be in writing. The form of proxy must be signed by the relevant Shareholder or by a person duly authorised by the relevant Shareholder in writing (a "**power of attorney**"). If the form of proxy is signed by the person authorised by the relevant Shareholder as aforesaid, the relevant power of attorney and other relevant documents of authorisation (if any) must be notarised. If a corporate Shareholder appoints a person other than its legal representative to attend the Extraordinary General Meeting (or any adjournment thereof) on its behalf, the relevant form of proxy must be affixed with the company seal/chop of the corporate Shareholder or duly signed by its director or any other person duly authorised by that corporate Shareholder as required by the Articles of Association.

4. To be valid, the form of proxy and the relevant notarised power of attorney (if any) and other relevant documents of authorisation (if any) as mentioned in note 3 above must be delivered to the Company's H share registrar in Hong Kong, Tricor Investor Services Limited at 17/F, Far East Finance Centre, 16 Harcourt Road, Hong Kong, not less than 24 hours before the time appointed for the Extraordinary General Meeting (or any adjournment thereof).

5. Each holder of Domestic Shares who is entitled to attend and vote at the Extraordinary General Meeting (or any adjournment thereof) may also, by completing the form of proxy of the Company, appoint one or more proxies to attend and vote at the Extraordinary General Meeting (or any adjournment thereof) on his behalf. A proxy needs not be a Shareholder. Notes 3 and 4 above also apply to the holders of Domestic Shares, except that, to be valid, the form of proxy and the relevant power of attorney (if any) and other relevant documents of authorisation (if any) must be delivered to the Secretary to the Board not less than 24 hours before the time appointed for the Extraordinary General Meeting (or any adjournment thereof). The address of the Secretary to the Board is stated in note 1 above.

6. A Shareholder or his proxy should produce proof of identity when attending the Extraordinary General Meeting (or any adjournment thereof). If a corporate Shareholder's legal representative or any other person authorised by the board of directors or other governing body of such corporate Shareholder attends the Extraordinary General Meeting (or any adjournment thereof), such legal representative or other person shall produce his proof of identity, and proof of designation as legal representative and the valid resolution or authorisation document of the board of directors or other governing body of such corporate Shareholder (as the case may be) to prove the identity and authorisation of that legal representative or other person.

7. It is expected that the Meeting will last not more than half day. Shareholders and their proxies attending the Meeting shall bear their own travel and accommodation expenses.